-A A +A
February 26, 2019

Canada is not a “free rider” on drug pricing according to a new report from the C.D. Howe Institute. In “High Drug Prices, Big R&D Spenders and “Free Riders”: Canada in the Topsy Turvy World of Pharmaceuticals”, authors Åke Blomqvist and Rosalie Wyonch find that relative to its peers, Canada does not free ride on US research and development spending.

Åke Blomqvist
Åke Blomqvist

Health Policy Scholar, C.D. Howe Institute

Rosalie Wyonch
Rosalie Wyonch

Rosalie has a Master of Arts in Economics and a Bachelor of Arts in Honours Mathematical Economics from the University of Waterloo. Prior to joining the C.D. Howe Institute in 2016, she was a Research Analyst at the Ontario Ministry of Finance in the Office of Economic Policy. Beginning in 2018, she became the director of the Health Policy Research Program and leads the C.D.